Not for human use, for research purposes only
Reference

Peptide Research Glossary

Definitions for common terms used in peptide research and chemistry. Browse alphabetically or search by topic.

A

A01

Acromegaly

Condition caused by excess growth hormone after growth plate closure.

A02

Amide bond / Amidation

C-terminal modification in some peptides (e.g CJC-1295) that improves stability against proteolysis.

A03

Angiogenesis

Formation of new blood vessels. BPC-157 modulates VEGF signalling in angiogenesis models.

B

B01

BAC water (Bacteriostatic water)

Sterile water containing 0.9% benzyl alcohol as a preservative that inhibits bacterial growth.

B02

BDNF (Brain-Derived Neurotrophic Factor)

Protein supporting neuron survival and growth. Semax increases BDNF expression in published models.

B03

BPC-157

Body Protection Compound-157. Pentadecapeptide derived from a gastric protein. No human clinical trials - all evidence from rodent models.

C

C01

cAMP (Cyclic AMP)

Intracellular signalling molecule. GHRH receptor activation triggers cAMP production, stimulating GH synthesis and release.

C02

CJC-1295

Modified GHRH analogue. "No DAC" version has ~30-minute half-life; "with DAC" (Drug Affinity Complex) extends half-life to 7-10 days by binding to albumin.

D

D01

DAC (Drug Affinity Complex)

A lysine-maleimide modification on CJC-1295 that covalently binds to circulating albumin, dramatically extending half-life from ~30 min to 7-10 days.

E

E01

Epithalon

Tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson. Studied for its effect on telomerase activity.

F

F01

Freeze-drying (lyophilization)

Process that removes water from peptides under vacuum to create a stable powder (lyophilisate). Allows long-term storage of the dry powder.

G

G01

GH (Growth Hormone / Somatotropin)

Protein hormone released by the pituitary. Stimulates IGF-1 production.

G02

GHRH (Growth Hormone-Releasing Hormone)

Hypothalamic peptide that stimulates GH synthesis and release from the pituitary. CJC-1295 and Sermorelin are GHRH analogues.

G03

GHRP (Growth Hormone-Releasing Peptide)

Class of synthetic peptides (Ipamorelin, GHRP-2, GHRP-6) that trigger GH release via ghrelin receptor (GHSR) activation. Mechanism independent of GHRH.

G04

GIP (Glucose-dependent Insulinotropic Polypeptide)

Incretin hormone. Tirzepatide is a dual GIP+GLP-1 agonist; the GIP component is the pharmacological difference from GLP-1-only agonists.

G05

GLP-1 (Glucagon-Like Peptide-1)

Incretin hormone that stimulates insulin release, suppresses glucagon, and delays gastric emptying. Semaglutide and Tirzepatide are GLP-1 agonists.

H

H01

Half-life

Time for plasma concentration to fall by 50%. Reported examples: Ipamorelin about 2 hours, CJC-1295 with DAC 7 to 10 days.

H02

HGH

Human Growth Hormone. A 191-amino-acid protein, identical in sequence to the endogenously produced hormone.

I

I01

IGF-1 (Insulin-Like Growth Factor 1)

Primary downstream mediator of GH action, produced mainly in the liver. Serum IGF-1 is the standard biomarker of GH-axis activity.

I02

IGF-1 LR3

Long R3 IGF-1. Modified IGF-1 with reduced IGFBP binding - ~3× longer half-life (~20h vs ~6h).

I03

Ipamorelin

Selective GHRP (ghrelin receptor agonist). Pentapeptide with high selectivity for GH release over cortisol and prolactin in published models.

L

L01

Lyophilisate

The dry powder produced by lyophilization (freeze-drying). The form in which peptides are supplied in sealed vials.

M

M01

Melanotan II

Cyclic analogue of α-MSH. Binds MC1R, MC3R, MC4R and MC5R without selectivity. No regulatory approval.

N

N01

NAD+ (Nicotinamide Adenine Dinucleotide)

Coenzyme central to cellular energy metabolism and DNA repair.

P

P01

Peptide

Short chain of amino acids (2-50) linked by peptide bonds. Most research peptides are 5-30 amino acids. Larger chains are proteins (HGH = 191 amino acids).

P02

Proteolysis

Enzymatic degradation of peptides by proteases in the body. Most peptides have very short half-lives due to rapid proteolytic breakdown. Chemical modifications (amidation, PEGylation, DAC) extend stability.

S

S01

Semaglutide

GLP-1 receptor agonist with C18 fatty-acid acylation. The STEP programme is its reference publication set.

S02

Sermorelin

GHRH analogue, full-length GHRH(1-44) with an N-terminal modification that resists DPP-4 cleavage.

T

T01

TB-500

Synthetic fragment of Thymosin Beta-4 (Tβ4). Promotes actin polymerization, cell migration, and anti-inflammatory signalling. No human clinical trials - animal model only.

T02

Tesamorelin

GHRH analogue: full-length GHRH(1-44) with an N-terminal trans-3-hexenoyl group that stabilises it against enzymatic cleavage.

T03

Thymosin Alpha-1

Immune-modulating peptide of 28 amino acids with an acetylated N-terminus, originally isolated from thymus tissue.

T04

Tirzepatide

Dual GIP and GLP-1 receptor agonist with C20 fatty-diacid acylation. SURMOUNT-1 is its reference publication.

V

V01

Vial (lyophilized)

Glass sealed container with lyophilized peptide powder. Common sizes: 1 mg, 2 mg, 5 mg, 10 mg.

Related Research Tools

Curated peptide stacks grouped by pathway.

Need Clarification?

Our team can help with terminology, product specifications and orders.